A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

• ClinicalTrials.gov Identifier: NCT06055439
• Recruitment Status: Not yet recruiting
• First Posted: September 26, 2023
• Last Update Posted: January 18, 2024
• Sponsor: Chimeric Therapeutics
• Information provided by (Responsible Party): Chimeric Therapeutics

Tracking Information

• First Submitted Date: September 13, 2023
• First Posted Date: September 26, 2023
• Last Update Posted Date: January 18, 2024
• Estimated Study Start Date: June 2024
• Estimated Primary Completion Date: June 2026 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 21, 2023)

• Dose-Limiting Toxicity (DLT) [ Time Frame: 28 Days ]
  Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
• Rates and Grades of Cytokine Release Syndrome (CRS) [ Time Frame: up to 15 years ]
  Assessed per American Society for Transplant and Cellular Therapy (ASTCT) consensus grading guideline
• All other adverse events and toxicities [ Time Frame: up to 15 years ]
  Assessed per NCI CTCAE v5.0
• Objective Response Rate (ORR) [ Time Frame: up to 15 years ]
  Assessed by RECIST v 1.1

Original Primary Outcome Measures (submitted: September 20, 2023)

• Dose-Limiting Toxicity (DLT) [ Time Frame: 28 Days ]
  Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
• Cytokine Release Syndrome (CRS) [ Time Frame: up to 15 years ]
  Assessed per American Society for Transplant and Cellular Therapy (ASTCT) consensus grading guideline, evaluating levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) (absolute number per µL by flowcytometry)
• All other adverse events and toxicities [ Time Frame: up to 15 years ]
  Assessed per NCI CTCAE v5.0
• Objective Response Rate (ORR) [ Time Frame: up to 15 years ]
  Assessed by RECIST v 1,1

Current Secondary Outcome Measures (submitted: December 18, 2023)

• Disease control rate (DCR) [ Time Frame: up to 15 years ]
  Assessed as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease to a therapeutic intervention in clinical trials of anticancer agents.
• Time to response (TTR) [ Time Frame: up to 15 years ]
  Measured as the amount of time elapsed until drug response is achieved for the first time.
• Duration of response (DOR) [ Time Frame: up to 15 years ]
  Measured as the amount of time a patient responds to a treatment before disease progresses or the patient dies.
• Progression-free survival (PFS) [ Time Frame: up to 15 years ]
  Measured from the date of first infusion of CAR-T cells until the first date when progressive disease (PD) is objectively documented or death from any cause, whichever is earlier.
• Overall survival (OS) [ Time Frame: up to 15 years ]
  Measured from the date of first infusion of CAR-T cells until death.

Original Secondary Outcome Measures (submitted: September 20, 2023)

• Disease control rate (DCR) [ Time Frame: up to 15 years ]
  Assessed as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.
• Time to response (TTR) [ Time Frame: up to 15 years ]
  Measured as the amount of time elapsed until drug response is achieved for the first time.
• Duration of response (DOR) [ Time Frame: up to 15 years ]
  Measured as the amount of time a patient responds to a treatment before disease progresses or the patient dies.
• Progression-free survival (PFS) [ Time Frame: up to 15 years ]
  Measured from the date of first infusion of CAR-T cells until the first date when progressive disease (PD) is objectively documented or death from any cause, whichever is earlier.
• Overall survival (OS) [ Time Frame: up to 15 years ]
  Measured from the date of first infusion of CAR-T cells until death.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
• Official Title: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers
• Brief Summary: The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

Detailed Description

This is a Phase 1/2 open-label study to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

The study has 2 parts: Phase 1, Dose Escalation and Expansion, and Phase 2. Potential participants will provide written consent and be screened for study eligibility prior to undergoing any screening procedures, including leukapheresis. Protocol-specified criteria must be met prior to the start of leukapheresis for collection of peripheral blood mononuclear cells (PBMCs). Eligible participants will undergo leukapheresis to collect PBMCs for product manufacturing, which comprises enrichment of T cells, lentiviral transduction, ex vivo expansion, and cryopreservation of the CHM-2101 cell product. Participants who have a leukapheresis or manufacturing failure may be permitted a second attempt at leukapheresis.

Bridging chemotherapy (treatment between the time of leukapheresis and first dose of lymphodepleting chemotherapy [LDC]) is permitted at the discretion of the investigator, if needed to maintain disease stability during CHM-2101 manufacturing time. Bridging chemotherapy is prohibited within the 2 weeks prior to leukapheresis and 2 weeks prior to planned CHM-2101 infusion. Specific criteria to proceed should be reviewed prior to leukapheresis, LDC, and CHM-2101 infusion. Participants will be followed in this study for 18 months or until disease progression.

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Neuroendocrine Tumors
• Colorectal Cancer
• Gastric Cancer

Intervention

Biological: CHM-2101 CAR-T cells

Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells

Study Arms

Experimental: Autologous CDH17 CAR T-cell Therapy

After receiving three daily doses of IV fludarabine and cyclophosphamide, participants will receive a single dose of IV CHM-2101.

The dose of CHM-2101 during Phase 1 will be based on "3+3" rules of dose escalation.

The recommended Phase 2 dose will be based on results from the Phase 1.

Intervention: Biological: CHM-2101 CAR-T cells

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Not yet recruiting
• Estimated Enrollment (submitted: September 20, 2023): 135
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: June 2027
• Estimated Primary Completion Date: June 2026 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Documented informed consent of the participant and/or legally authorized representative.

2. Confirmed histologic diagnosis of one of the following solid tumors of GI origin:

   1. Gastric adenocarcinoma Note: for gastric adenocarcinoma patients only, central laboratory confirmation of CDH17+ tumor expression is required.
   2. Colon and/or rectal adenocarcinoma
   3. G1, G2, and well-differentiated G3 neuroendocrine tumors of the midgut and hindgut (ileal, jejunal, cecal, distal colonic, or rectal; with ≤ 55% Ki67 expression)
3. Availability of unstained tumor tissue slides from archived tumor tissue or a new tumor biopsy, if medically feasible. Note: for gastric adenocarcinoma patients only, confirmation of CDH17+ is required prior to study inclusion.
4. Have received at least 1 prior line of systemic anti-cancer treatment in the locally advanced or metastatic setting, as defined by National Comprehensive Cancer Network (NCCN) guidelines. Participants must have received or declined FDA-approved and available treatment options, including targeted therapies for disease mutation or antigen expression status.
5. Age ≥ 18 years and ≤ 85 years.
6. For Phase 1 Dose Expansion and Phase 2 only: Measurable disease as per RECIST v1.1 criteria (Note: Measurable disease is NOT required for Phase 1 Dose Escalation).
7. Eastern Cooperative Oncology Group (ECOG) ≤ 1.
8. Life expectancy ≥ 12 weeks.
9. No known contraindications to leukapheresis, cyclophosphamide, fludarabine, or steroids.

10. Baseline laboratory values as shown in the following table:

    Minimum Laboratory Values for Study Entry Laboratory Assessment Criteria White blood cell count > 4,000/mm3 Absolute neutrophil count (ANC) ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Hemoglobin ≥ 10 g/dL Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate amino transferase (AST) ≤ 3 x ULN Alanine transaminase (ALT) ≤ 3 x ULN Creatinine clearance by Cockroft-Gault equation 60 mL/min Oxygen saturation ≥ 92% on room air Albumin ≥ 3 g/dL

11. Left ventricular ejection fraction ≥ 50%.
12. Seronegative for human immunodeficiency virus (HIV) by antigen/antibody (Ag/Ab) testing.
13. Seronegative for hepatitis B and/or hepatitis C virus.
14. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
15. Agreement by women and men of childbearing potential to use an effective method of birth control or abstain from heterosexual activity through at least 3 months after the last dose of CHM-2101.

Exclusion Criteria:

1. Previous treatment with CDH17-targeted therapies.
2. Unresolved toxicities from prior therapy except for chronic toxicity no greater than Grade 1 and stable > 30 days (Note: alopecia of any grade is not exclusionary).
3. Uncontrolled seizure activity and/or known central nervous system (CNS) metastases.
4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
5. Uncontrolled Crohn's disease, ulcerative colitis, or other autoimmune or inflammatory disorders of the GI tract. "Uncontrolled" is defined as requiring hospitalization, corticosteroids, or chronic medication increase (dosage or frequency) within the previous 6 months.
6. Liver involvement ≥ 50%.
7. Active infection requiring oral or IV antibiotics.
8. Current diagnosis of pleural effusions, interstitial lung disease, or heart failure of New York Heart Association Classification of Heart Failure Class III or IV.
9. Ongoing treatment with systemic corticosteroid therapy at doses of prednisone ≥ 20 mg/day or equivalent (lower doses of corticosteroid therapy are allowed until 7 days prior to leukapheresis).
10. No prior malignancy within 5 years except for non-melanomatous skin cancer or cervical cancer treated with curative intent
11. Currently breastfeeding or planning to become pregnant within 9 months of study enrollment.
12. Any other clinically significant uncontrolled illness or other comorbid condition that would, in the investigator's judgment, contraindicate the participant's participation in the clinical study.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 85 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Jason B Litten, MD; (415) 802-4360; jlitten@chimerictherapeutics.com

• Listed Location Countries: Not Provided

Administrative Information

• NCT Number: NCT06055439
• Other Study ID Numbers: CHM-2101-001
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Chimeric Therapeutics
• Original Responsible Party: Same as current
• Current Study Sponsor: Chimeric Therapeutics
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Jennifer Eads, MD; University of Pennsylvania
• Principal Investigator: Michael R Bishop, MD; University of Chicago

• PRS Account: Chimeric Therapeutics
• Verification Date: January 2024